حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Selvita S.A.
SLVSelvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, autoimmune/immunology, neurology, respiratory, and other. In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services. Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry. Selvita S.A. was founded in 2007 and is headquartered in Kraków, Poland. Address: Hexagon, Kraków, Poland, 30-394
Analytics
سعر الهدف في وول ستريت
279.97 PLNنسبة السعر إلى الأرباح
21.5891العائد الربحي
–السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية SLV
تحليلات الأرباح SLV
نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–تاريخ الأرباح SLV
تقييم الأسهم SLV
المالية SLV
نتائج | 2019 | ديناميات |